| SM ISO690:2012|
TOMACINSCHII, Victor; ROBU, Maria; MUSTEAŢĂ, Vasile; MOCANU, Irina; SPORÎŞ, Natalia; FEGHIU, Veronica. Secondary acute promielocytic leukemia developed after treatment of non-hodgkin's lymphoma, case study and review of literature. In: Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”. 21-23 octombrie 2020, Chişinău. Chişinău: USMF, 2020, p. 270.
|Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu” 2020|
Congresul "Congresul consacrat aniversării a 75-a de la fondarea Universității de Stat de Medicină şi Farmacie „Nicolae Testemiţanu”" |
Chişinău, Moldova, 21-23 octombrie 2020
Background. Acute promyelocytic leukemia (APL) is an acute myeloid leukemia (AML) that accounts approximately 10-15% of AML cases. APL usually appears as an de novo finding. The occurrence of secondary APL(sAPL) after chemotherapy(PChT) is rare, and the development of sAPL after an NHL is casuistic. Objective of the study. Description of a case of sAPL after NHL therapy. Material and Methods. The morphological blocks of lymph node biopsy, CBC and bone marrow aspiration (bma) were investigated. Results. Male B, 34 years old, hospitalized in a critical condition in the hematological center with Diffuse large B cell lymphoma, stage IV B, X (Ann-Arbor). With the purpose of induction, PChT cures were performed: R-CHOP, R-CHOEP, CVP, obtaining partial remission. 25 months after the onset of NHL, the patient experienced: anemia, thrombocytopenia, leukocytosis associated with peripheral blastosis. For restadialization an bma was performed, which reveals 95% of promyelocytetype blasts. sAPL was confirmed, induction PChT was initiated, still the result proved no efficacy. The death occurred early in induction, which corresponds with literature data. Conclusion. sAPL after NHL therapy are rare nosological entities in clinical practice, which are associated with the negative effect of treatment with anthracyclines or tenoposide derivatives, results in unfavorable prognosis and high mortality.
secondary acute promyelocytic leukemia, non-Hodgkin's lymphoma,
leucemie acută promielocitară secundară, limfom non-Hodgkin